148 related articles for article (PubMed ID: 38697830)
1. Parathyroid tumors in the 5th edition of the WHO Classification of Tumors of the Endocrine Organs.
J D
Cesk Patol; 2024; 60(1):68-70. PubMed ID: 38697830
[TBL] [Abstract][Full Text] [Related]
2. Overview of the 2022 WHO Classification of Parathyroid Tumors.
Erickson LA; Mete O; Juhlin CC; Perren A; Gill AJ
Endocr Pathol; 2022 Mar; 33(1):64-89. PubMed ID: 35175514
[TBL] [Abstract][Full Text] [Related]
3. Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors.
Cetani F; Marcocci C; Torregrossa L; Pardi E
Endocr Relat Cancer; 2019 Jul; 26(7):R441-R464. PubMed ID: 31085770
[TBL] [Abstract][Full Text] [Related]
4. Advances and Updates in Parathyroid Pathology.
Gokozan HN; Scognamiglio T
Adv Anat Pathol; 2023 Jan; 30(1):24-33. PubMed ID: 36315270
[TBL] [Abstract][Full Text] [Related]
5. Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.
Cetani F; Pardi E; Ambrogini E; Banti C; Viacava P; Borsari S; Bilezikian JP; Pinchera A; Marcocci C
J Endocrinol Invest; 2008 Oct; 31(10):900-4. PubMed ID: 19092296
[TBL] [Abstract][Full Text] [Related]
6. Para This, Fibromin That: The Role of CDC73 in Parathyroid Tumors and Familial Tumor Syndromes.
Ababneh E; Nosé V
Surg Pathol Clin; 2023 Mar; 16(1):97-105. PubMed ID: 36739170
[TBL] [Abstract][Full Text] [Related]
7. Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features.
Gill AJ; Lim G; Cheung VKY; Andrici J; Perry-Keene JL; Paik J; Sioson L; Clarkson A; Sheen A; Luxford C; Elston MS; Meyer-Rochow GY; Nano MT; Kruijff S; Engelsman AF; Sywak M; Sidhu SB; Delbridge LW; Robinson BG; Marsh DJ; Toon CW; Chou A; Clifton-Bligh RJ
Am J Surg Pathol; 2019 Jan; 43(1):35-46. PubMed ID: 29324469
[TBL] [Abstract][Full Text] [Related]
8. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification.
Juhlin CC; Villablanca A; Sandelin K; Haglund F; Nordenström J; Forsberg L; Bränström R; Obara T; Arnold A; Larsson C; Höög A
Endocr Relat Cancer; 2007 Jun; 14(2):501-12. PubMed ID: 17639063
[TBL] [Abstract][Full Text] [Related]
9. [Clinical and morphological characteristics of parathyroid carcinoma].
Voronkova IA; Mokrysheva NG; Kazantseva IA; Gurevich LE
Arkh Patol; 2018; 80(4):65-72. PubMed ID: 30059074
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic Profiling and Molecular Mechanisms in Hyperparathyroidism-jaw Tumor Syndrome.
Tora R; Welch J; Sun J; Agarwal SK; Bell DA; Merino M; Weinstein LS; Simonds WF; Jha S
J Clin Endocrinol Metab; 2023 Nov; 108(12):3165-3177. PubMed ID: 37339334
[TBL] [Abstract][Full Text] [Related]
11. Changes in the diagnosis of thyroid tumours in the 5th edition of the WHO classification of endocrine neoplasms.
J D
Cesk Patol; 2024; 60(1):59-63. PubMed ID: 38697828
[TBL] [Abstract][Full Text] [Related]
12. Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation.
Kelly TG; Shattuck TM; Reyes-Mugica M; Stewart AF; Simonds WF; Udelsman R; Arnold A; Carpenter TO
J Bone Miner Res; 2006 Oct; 21(10):1666-71. PubMed ID: 16995822
[TBL] [Abstract][Full Text] [Related]
13. CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.
Guarnieri V; Battista C; Muscarella LA; Bisceglia M; de Martino D; Baorda F; Maiello E; D'Agruma L; Chiodini I; Clemente C; Minisola S; Romagnoli E; Corbetta S; Viti R; Eller-Vainicher C; Spada A; Iacobellis M; Malavolta N; Carella M; Canaff L; Hendy GN; Cole DE; Scillitani A
Cell Oncol (Dordr); 2012 Dec; 35(6):411-22. PubMed ID: 22987117
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide and locus specific alterations in CDC73/HRPT2-mutated parathyroid tumors.
Sulaiman L; Haglund F; Hashemi J; Obara T; Nordenström J; Larsson C; Juhlin CC
PLoS One; 2012; 7(9):e46325. PubMed ID: 23029479
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid tumors and related disorders.
DeLellis RA
Mod Pathol; 2011 Apr; 24 Suppl 2():S78-93. PubMed ID: 21455204
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a novel CDC73 gene mutation in a hyperparathyrodism-jaw tumor patient affected by parathyroid carcinoma in the absence of somatic loss of heterozygosity.
Ciuffi S; Cianferotti L; Nesi G; Luzi E; Marini F; Giusti F; Zonefrati R; Gronchi G; Perigli G; Brandi ML
Endocr J; 2019 Apr; 66(4):319-327. PubMed ID: 30799315
[TBL] [Abstract][Full Text] [Related]
17. Insights into Hyperparathyroidism-Jaw Tumour Syndrome: From Endocrine Acumen to the Spectrum of
Gheorghe AM; Sima OC; Florescu AF; Ciuche A; Nistor C; Sandru F; Carsote M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396977
[TBL] [Abstract][Full Text] [Related]
18. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
Gill AJ; Clarkson A; Gimm O; Keil J; Dralle H; Howell VM; Marsh DJ
Am J Surg Pathol; 2006 Sep; 30(9):1140-9. PubMed ID: 16931959
[TBL] [Abstract][Full Text] [Related]
19. Do Patients With Atypical Parathyroid Adenoma Need Close Follow-up?
Saponaro F; Pardi E; Mazoni L; Borsari S; Torregrossa L; Apicella M; Frustaci G; Materazzi G; Miccoli P; Basolo F; Marcocci C; Cetani F
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4565-e4579. PubMed ID: 34157106
[TBL] [Abstract][Full Text] [Related]
20. Challenging lesions in the differential diagnosis of endocrine tumors: parathyroid carcinoma.
Delellis RA
Endocr Pathol; 2008; 19(4):221-5. PubMed ID: 19058032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
